168 related articles for article (PubMed ID: 38401902)
1. Canadian Addiction Treatment Centre (CATC) opioid agonist treatment cohort in Ontario, Canada.
Morin KA; Tatangelo M; Marsh D
BMJ Open; 2024 Feb; 14(2):e080790. PubMed ID: 38401902
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the gap in delivery of opioid agonist therapy among individuals with opioid-related health problems: a population-based retrospective cohort study.
Paul LA; Bayoumi AM; Chen C; Kocovska E; Smith BT; Raboud JM; Gomes T; Kendall C; Rosella LC; Bitonti-Bengert L; Rush B; Yu M; Spithoff S; Crichlow F; Wright A; Watford J; Besharah J; Munro C; Taha S; Nosyk B; Strike C; Manson H; Kahan M; Leece P
Addiction; 2023 Apr; 118(4):686-697. PubMed ID: 36401610
[TBL] [Abstract][Full Text] [Related]
3. Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: A population-based time-series analysis.
Kitchen SA; Campbell TJ; Men S; Bozinoff N; Tadrous M; Antoniou T; Wyman J; Werb D; Munro C; Gomes T
Int J Drug Policy; 2022 May; 103():103644. PubMed ID: 35272107
[TBL] [Abstract][Full Text] [Related]
4. Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study.
Gomes T; McCormack D; Bozinoff N; Tadrous M; Antoniou T; Munro C; Campbell T; Paterson JM; Mamdani M; Sproule B
Addiction; 2022 Jul; 117(7):1972-1981. PubMed ID: 35257434
[TBL] [Abstract][Full Text] [Related]
5. Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study.
Russell C; Nafeh F; Pang M; MacDonald SF; Derkzen D; Rehm J; Fischer B
BMC Public Health; 2022 Mar; 22(1):436. PubMed ID: 35246083
[TBL] [Abstract][Full Text] [Related]
6. A population-based time-series analysis of opioid agonist treatment dispensed during pregnancy.
Schmidt RA; Everett K; Perez-Brumer A; Strike C; Rush B; Gomes T
Addiction; 2024 Jun; 119(6):1111-1122. PubMed ID: 38476027
[TBL] [Abstract][Full Text] [Related]
7. Impact of the COVID-19 pandemic on the prevalence of opioid agonist therapy discontinuation in Ontario, Canada: A population-based time series analysis.
Garg R; Kitchen SA; Men S; Campbell TJ; Bozinoff N; Tadrous M; Antoniou T; Wyman J; Werb D; Munro C; Gomes T
Drug Alcohol Depend; 2022 Jul; 236():109459. PubMed ID: 35489179
[TBL] [Abstract][Full Text] [Related]
8. Opioid agonist therapy switching among individuals with prescription-type opioid use disorder: Secondary analysis of a pragmatic randomized trial.
Mocanu V; Bozinoff N; Wood E; Jutras-Aswad D; Le Foll B; Lim R; Cheol Choi J; Yin Mok W; Eugenia Socias M;
Drug Alcohol Depend; 2023 Jul; 248():109932. PubMed ID: 37224674
[TBL] [Abstract][Full Text] [Related]
9. Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions.
Bouck Z; Scheim AI; Gomes T; Ling V; Caudarella A; Werb D
Int J Drug Policy; 2022 Jun; 104():103680. PubMed ID: 35447476
[TBL] [Abstract][Full Text] [Related]
10. Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province.
Sadek J; Saunders J
BMC Psychiatry; 2022 Jul; 22(1):516. PubMed ID: 35908052
[TBL] [Abstract][Full Text] [Related]
11. Trends in engagement in the cascade of care for opioid use disorder, Vancouver, Canada, 2006-2016.
Socías ME; Wood E; Kerr T; Nolan S; Hayashi K; Nosova E; Montaner J; Milloy MJ
Drug Alcohol Depend; 2018 Aug; 189():90-95. PubMed ID: 29894910
[TBL] [Abstract][Full Text] [Related]
12. The cascade of care for opioid use disorder: a retrospective study in British Columbia, Canada.
Piske M; Zhou H; Min JE; Hongdilokkul N; Pearce LA; Homayra F; Socias ME; McGowan G; Nosyk B
Addiction; 2020 Aug; 115(8):1482-1493. PubMed ID: 31899565
[TBL] [Abstract][Full Text] [Related]
13. Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation.
Gomes T; Campbell TJ; Kitchen SA; Garg R; Bozinoff N; Men S; Tadrous M; Munro C; Antoniou T; Werb D; Wyman J
JAMA; 2022 Mar; 327(9):846-855. PubMed ID: 35230394
[TBL] [Abstract][Full Text] [Related]
14. The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale.
Socias ME; Ahamad K; Le Foll B; Lim R; Bruneau J; Fischer B; Wild TC; Wood E; Jutras-Aswad D
Contemp Clin Trials; 2018 Jun; 69():21-27. PubMed ID: 29627621
[TBL] [Abstract][Full Text] [Related]
15. Measuring treatment attrition at various stages of engagement in Opioid Agonist Treatment in Ontario Canada using a cascade of care framework.
Tahsin F; Morin KA; Vojtesek F; Marsh DC
BMC Health Serv Res; 2022 Apr; 22(1):490. PubMed ID: 35413980
[TBL] [Abstract][Full Text] [Related]
16. Characterizing opioid agonist treatment discontinuation trends in British Columbia, Canada, 2012-2018.
Krebs E; Homayra F; Min JE; MacDonald S; Gold L; Carter C; Nosyk B
Drug Alcohol Depend; 2021 Aug; 225():108799. PubMed ID: 34087747
[TBL] [Abstract][Full Text] [Related]
17. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
[TBL] [Abstract][Full Text] [Related]
18. Initiating opioid agonist treatment for opioid use disorder nationally in the Veterans Health Administration: Who gets what?
Manhapra A; Stefanovics E; Rosenheck R
Subst Abus; 2020; 41(1):110-120. PubMed ID: 31403914
[No Abstract] [Full Text] [Related]
19. Initiation of opioid agonist therapy after hospital visits for opioid poisonings in Ontario.
Hu T; McCormack D; Juurlink DN; Campbell TJ; Bayoumi AM; Leece P; Kent JT; Gomes T
CMAJ; 2023 Dec; 195(49):E1709-E1717. PubMed ID: 38110219
[TBL] [Abstract][Full Text] [Related]
20. Changes in Opioid Agonist Treatment Practice in Germany during the COVID-19 Pandemic: What Have Physicians Done, and What Would They Like to Keep Doing?
Lehmann K; Kuhn S; Schulte B; Verthein U
Eur Addict Res; 2023; 29(5):323-332. PubMed ID: 37557092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
